30 closest matches · ranked by relevance
Influenza
Primary: Number of Participants With Laboratory-Confirmed Clinical Influenza, ITT Population — 7; 5 participants — p=0.772
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Pulmonary Disease, Chronic Obstructive · Bronchospasm · Influenza, Human
Primary: Number of Patients With Influenza — 3; 10; 2539; 93 patients
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Influenza Viral Infections
Primary: Incidence of Symptomatic Influenza Infection — 6; 6; 16; 12 Participants — p=0.0331
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Influenza, Human
Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069
Influenza
Primary: Duration of Influenza Illness — 4; 4 days
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Influenza
Primary: Time to Resolution of All Clinical Symptoms of Influenza as Reported by the Subjects — 109.1; 116.7; 95.5 Hours
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Influenza A Virus Infection
Primary: Clinical Status at Day 7 — 2; 2; 15; 10 Participants — p=0.54
Influenza
Primary: Total All-cause Hospitalizations — 197; 301 events
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
Influenza, Human
Primary: Number of Subjects With Immediate Adverse Events — 0; 0 Participants
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Acute, Uncomplicated Human Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 106.9; 91.1 hours — p=0.222